Evaluation of the oral Nicorandil effect on reducing the contrast-induced
Phase 3
Recruiting
- Conditions
- cardiac catheterization.
- Registration Number
- IRCT20210620051631N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 344
Inclusion Criteria
Based on the risk score,Have a moderate risk or at least two risk factors for contrast nephropathy.
EF less than 40
Diabetes mellitus.
Blood pressure above 140/90 mm Hg,
Renal failure (GFR) less than 60
No pregnancy
(basal serum creatinine above 1.5 mg / dl)
Minimum age 18
Exclusion Criteria
Pregnancy
Pulmonary edema
Cardiogenic shock
Multiple myeloma
Acute renal failure
ESRD(GFR<15 mg/dl)
Allergy to media contrast
Nicorandil allergy
Facing media contrast in the last 7 days
NAC and metformin and dopamine and sodium bicarbonate and mannitol and phenol dopam in the last 48 hours
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method aboratory banksHb, FBS, HCT, TG, LDL, HDL,ChoL. Timepoint: The first step at the beginning of the study. Method of measurement: Sampling.
- Secondary Outcome Measures
Name Time Method Serum creatinine and creatinine clearance and BUN. Timepoint: It is measured 24 to 48 hours after the procedure. Method of measurement: Protocol based analysis.